We leverage our deep knowledge of underlying biological processes to develop innovative and disruptive technology, with proprietary small molecule drug candidates that directly target lysosomal functions, implicated in the growth, spread and resistance of cancers. We currently retain global development and commercialization rights of GNS561.
